|Day Low/High||162.50 / 165.15|
|52 Wk Low/High||114.27 / 197.00|
The ActionAlertsPLUS team breaks down what investors need to know on Tueday, including: AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.
After days of complacency, we see a shift in sentiment and folks are getting the jitters.
AbbVie takes over Allergan. But, it's not the biggest deal of 2019...
Major indexes declined Tuesday after Federal Reserve Chairman Jerome Powell hedged on a possible rate cut.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
AbbVie to purchase botox maker Allergan in $63 billion deal, but is the price just right?
Allergan shares surged the most in more than 25 years Tuesday after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie .
With no other bidder expected to emerge, this is a high risk arbitrage play.
AbbVie is Real Money's Stock of the Day. The biopharmaceutical giant announced a planned $63 billion takeover of Allergan. Action Alerts PLUS Senior Portfolio Analyst Jeff Marks breaks down what investors need to know about the deal.
PFE was ready to pay $160 billion until U.S. regulators blocked the deal.
Wall Street woke up to another major deal. Here's what to watch from AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
Let's look closer at the charts and indicators of ABBV.
U.S. equity futures drifted lower Tuesday, setting up the S&P 500 for its first three-day decline since early May, as investors peel back from recent record highs and take a defensive stance on risk ahead of this weekend's G20 Summit in Japan.
AbbVie is dropping on Allergan deal announcement, momentum is weak outside certain pockets.
U.S. stock futures decline as investors take a defensive stance on risk ahead of this weekend's G-20 summit in Japan; Micron reports earnings Tuesday; FedEx, which also reports earnings, sues the U.S. government arguing new trade regulations put an 'impossible burden' on the company to monitor its shipments.
The intermediate-term sentiment indicators don’t show too much giddiness -- yet -- but look at all the market has on its plate this week.
Aegon will repurchase 32,873,805 common shares to neutralize the dilutive effect of the 2018 final stock dividend.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE:AGN) today announced positive topline data from a Phase IIIb clinical trial evaluating LINZESS (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with IBS-C.
Today, Aegon Bank priced its inaugural EUR 500 million 5 year Senior Non-Preferred notes with a yield of 0.
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin
A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.
Investors should consider recession-proof names in the current environment, Jim Cramer says.
South Korea is the plastic surgery capital of the world. These companies are manufacturing botox strains - but the big business is abroad, if they can crack the China and U.S. markets.
Aegon today announces that Sarah Russell (1962, Australian), member of Aegon's Management Board and Global CEO of Aegon Asset Management, will step down.
- New Indication Makes VRAYLAR First and Only Dopamine and Serotonin Partial Agonist to Treat the Full Spectrum of Bipolar I Symptoms in Manic, Mixed, and Depressive Episodes -
DUBLIN, May 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35 th Annual Strategic Decisions Conference in New York, NY.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.